Procalcitonin-guided antibiotic therapy reduces antibiotic use for lower respiratory tract infections in a United States medical center: Results of a clinical trial

Jennifer Townsend, Victoria Adams, Panagis Galiatsatos, David B Pearse, Hardin Pantle, Mary Masterson, Flora Kisuule, Elsen Jacob, Catherine Kiruthi, Paul Ortiz, Albert Agbanlog, Robert Jurao, Sam Stern, Seema Nayak, Michael Melgar, Jacob Sama, Jillian Irwin, Cyrus Mazidi, Kevin Psoter, Robin McKenzie

Research output: Contribution to journalArticle

Abstract

Background. European trials using procalcitonin (PCT)-guided antibiotic therapy for patients with lower respiratory tract infections (LRTIs) have demonstrated significant reductions in antibiotic use without increasing adverse outcomes. Few studies have examined PCT for LRTIs in the United States. Methods. In this study, we evaluated whether a PCT algorithm would reduce antibiotic exposure in patients with LRTI in a US hospital. We conducted a controlled pre-post trial comparing an intervention group of PCT-guided antibiotic therapy to a control group of usual care. Consecutive patients admitted to medicine services and receiving antibiotics for LRTI were enrolled in the intervention. Providers were encouraged to discontinue antibiotics according to a PCT algorithm. Control patients were similar patients admitted before the intervention. Results. The primary endpoint was median antibiotic duration. Overall adverse outcomes at 30 days comprised death, transfer to an intensive care unit, antibiotic side effects, Clostridium difficile infection, disease-specific complications, and post-discharge antibiotic prescription for LRTI. One hundred seventy-four intervention patients and 200 controls were enrolled. Providers complied with the PCT algorithm in 75% of encounters. Procalcitonin-guided therapy reduced median antibiotic duration for pneumonia from 7 days to 6 (P = .045) and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) from 4 days to 3 (P = .01). There was no difference in the rate of adverse outcomes in the PCT and control groups. Conclusions. A PCT-guided algorithm safely reduced the duration of antibiotics for treating LRTI. Utilization of a PCT algorithm may aid antibiotic stewardship efforts. This clinical trial was a single-center, controlled, pre-post study of PCT-guided antibiotic therapy for LRTI. The intervention (incorporation of PCT-guided algorithms) started on April 1, 2017: the preintervention (control group) comprised patients admitted from November 1, 2016 to April 16, 2017, and the postintervention group comprised patients admitted from April 17, 2017 to November 29, 2017 (Supplementary Figure 1). The study comprised patients admitted to the internal medicine services to a medical ward, the Medical Intensive Care Unit (MICU), the Cardiac Intensive Care Unit (CICU), or the Progressive Care Unit (PCU) “step down unit”. The registration data for the trails are in the ClinicalTrials.gov database, number NCT0310910.

Original languageEnglish (US)
JournalOpen Forum Infectious Diseases
Volume5
Issue number12
DOIs
StatePublished - Jan 1 2018

Fingerprint

Calcitonin
Respiratory Tract Infections
Clinical Trials
Anti-Bacterial Agents
Therapeutics
Intensive Care Units
Control Groups
Clostridium Infections
Clostridium difficile
Internal Medicine
Chronic Obstructive Pulmonary Disease
Prescriptions
Pneumonia
Medicine
Databases

Keywords

  • Antibiotic stewardship
  • Clinical trials
  • Lower respiratory tract infections
  • Procalcitonin

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Cite this

Procalcitonin-guided antibiotic therapy reduces antibiotic use for lower respiratory tract infections in a United States medical center : Results of a clinical trial. / Townsend, Jennifer; Adams, Victoria; Galiatsatos, Panagis; Pearse, David B; Pantle, Hardin; Masterson, Mary; Kisuule, Flora; Jacob, Elsen; Kiruthi, Catherine; Ortiz, Paul; Agbanlog, Albert; Jurao, Robert; Stern, Sam; Nayak, Seema; Melgar, Michael; Sama, Jacob; Irwin, Jillian; Mazidi, Cyrus; Psoter, Kevin; McKenzie, Robin.

In: Open Forum Infectious Diseases, Vol. 5, No. 12, 01.01.2018.

Research output: Contribution to journalArticle

Townsend, Jennifer ; Adams, Victoria ; Galiatsatos, Panagis ; Pearse, David B ; Pantle, Hardin ; Masterson, Mary ; Kisuule, Flora ; Jacob, Elsen ; Kiruthi, Catherine ; Ortiz, Paul ; Agbanlog, Albert ; Jurao, Robert ; Stern, Sam ; Nayak, Seema ; Melgar, Michael ; Sama, Jacob ; Irwin, Jillian ; Mazidi, Cyrus ; Psoter, Kevin ; McKenzie, Robin. / Procalcitonin-guided antibiotic therapy reduces antibiotic use for lower respiratory tract infections in a United States medical center : Results of a clinical trial. In: Open Forum Infectious Diseases. 2018 ; Vol. 5, No. 12.
@article{00dcd95287274d469890b389e29544f4,
title = "Procalcitonin-guided antibiotic therapy reduces antibiotic use for lower respiratory tract infections in a United States medical center: Results of a clinical trial",
abstract = "Background. European trials using procalcitonin (PCT)-guided antibiotic therapy for patients with lower respiratory tract infections (LRTIs) have demonstrated significant reductions in antibiotic use without increasing adverse outcomes. Few studies have examined PCT for LRTIs in the United States. Methods. In this study, we evaluated whether a PCT algorithm would reduce antibiotic exposure in patients with LRTI in a US hospital. We conducted a controlled pre-post trial comparing an intervention group of PCT-guided antibiotic therapy to a control group of usual care. Consecutive patients admitted to medicine services and receiving antibiotics for LRTI were enrolled in the intervention. Providers were encouraged to discontinue antibiotics according to a PCT algorithm. Control patients were similar patients admitted before the intervention. Results. The primary endpoint was median antibiotic duration. Overall adverse outcomes at 30 days comprised death, transfer to an intensive care unit, antibiotic side effects, Clostridium difficile infection, disease-specific complications, and post-discharge antibiotic prescription for LRTI. One hundred seventy-four intervention patients and 200 controls were enrolled. Providers complied with the PCT algorithm in 75{\%} of encounters. Procalcitonin-guided therapy reduced median antibiotic duration for pneumonia from 7 days to 6 (P = .045) and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) from 4 days to 3 (P = .01). There was no difference in the rate of adverse outcomes in the PCT and control groups. Conclusions. A PCT-guided algorithm safely reduced the duration of antibiotics for treating LRTI. Utilization of a PCT algorithm may aid antibiotic stewardship efforts. This clinical trial was a single-center, controlled, pre-post study of PCT-guided antibiotic therapy for LRTI. The intervention (incorporation of PCT-guided algorithms) started on April 1, 2017: the preintervention (control group) comprised patients admitted from November 1, 2016 to April 16, 2017, and the postintervention group comprised patients admitted from April 17, 2017 to November 29, 2017 (Supplementary Figure 1). The study comprised patients admitted to the internal medicine services to a medical ward, the Medical Intensive Care Unit (MICU), the Cardiac Intensive Care Unit (CICU), or the Progressive Care Unit (PCU) “step down unit”. The registration data for the trails are in the ClinicalTrials.gov database, number NCT0310910.",
keywords = "Antibiotic stewardship, Clinical trials, Lower respiratory tract infections, Procalcitonin",
author = "Jennifer Townsend and Victoria Adams and Panagis Galiatsatos and Pearse, {David B} and Hardin Pantle and Mary Masterson and Flora Kisuule and Elsen Jacob and Catherine Kiruthi and Paul Ortiz and Albert Agbanlog and Robert Jurao and Sam Stern and Seema Nayak and Michael Melgar and Jacob Sama and Jillian Irwin and Cyrus Mazidi and Kevin Psoter and Robin McKenzie",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/ofid/ofy327",
language = "English (US)",
volume = "5",
journal = "Open Forum Infectious Diseases",
issn = "2328-8957",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Procalcitonin-guided antibiotic therapy reduces antibiotic use for lower respiratory tract infections in a United States medical center

T2 - Results of a clinical trial

AU - Townsend, Jennifer

AU - Adams, Victoria

AU - Galiatsatos, Panagis

AU - Pearse, David B

AU - Pantle, Hardin

AU - Masterson, Mary

AU - Kisuule, Flora

AU - Jacob, Elsen

AU - Kiruthi, Catherine

AU - Ortiz, Paul

AU - Agbanlog, Albert

AU - Jurao, Robert

AU - Stern, Sam

AU - Nayak, Seema

AU - Melgar, Michael

AU - Sama, Jacob

AU - Irwin, Jillian

AU - Mazidi, Cyrus

AU - Psoter, Kevin

AU - McKenzie, Robin

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background. European trials using procalcitonin (PCT)-guided antibiotic therapy for patients with lower respiratory tract infections (LRTIs) have demonstrated significant reductions in antibiotic use without increasing adverse outcomes. Few studies have examined PCT for LRTIs in the United States. Methods. In this study, we evaluated whether a PCT algorithm would reduce antibiotic exposure in patients with LRTI in a US hospital. We conducted a controlled pre-post trial comparing an intervention group of PCT-guided antibiotic therapy to a control group of usual care. Consecutive patients admitted to medicine services and receiving antibiotics for LRTI were enrolled in the intervention. Providers were encouraged to discontinue antibiotics according to a PCT algorithm. Control patients were similar patients admitted before the intervention. Results. The primary endpoint was median antibiotic duration. Overall adverse outcomes at 30 days comprised death, transfer to an intensive care unit, antibiotic side effects, Clostridium difficile infection, disease-specific complications, and post-discharge antibiotic prescription for LRTI. One hundred seventy-four intervention patients and 200 controls were enrolled. Providers complied with the PCT algorithm in 75% of encounters. Procalcitonin-guided therapy reduced median antibiotic duration for pneumonia from 7 days to 6 (P = .045) and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) from 4 days to 3 (P = .01). There was no difference in the rate of adverse outcomes in the PCT and control groups. Conclusions. A PCT-guided algorithm safely reduced the duration of antibiotics for treating LRTI. Utilization of a PCT algorithm may aid antibiotic stewardship efforts. This clinical trial was a single-center, controlled, pre-post study of PCT-guided antibiotic therapy for LRTI. The intervention (incorporation of PCT-guided algorithms) started on April 1, 2017: the preintervention (control group) comprised patients admitted from November 1, 2016 to April 16, 2017, and the postintervention group comprised patients admitted from April 17, 2017 to November 29, 2017 (Supplementary Figure 1). The study comprised patients admitted to the internal medicine services to a medical ward, the Medical Intensive Care Unit (MICU), the Cardiac Intensive Care Unit (CICU), or the Progressive Care Unit (PCU) “step down unit”. The registration data for the trails are in the ClinicalTrials.gov database, number NCT0310910.

AB - Background. European trials using procalcitonin (PCT)-guided antibiotic therapy for patients with lower respiratory tract infections (LRTIs) have demonstrated significant reductions in antibiotic use without increasing adverse outcomes. Few studies have examined PCT for LRTIs in the United States. Methods. In this study, we evaluated whether a PCT algorithm would reduce antibiotic exposure in patients with LRTI in a US hospital. We conducted a controlled pre-post trial comparing an intervention group of PCT-guided antibiotic therapy to a control group of usual care. Consecutive patients admitted to medicine services and receiving antibiotics for LRTI were enrolled in the intervention. Providers were encouraged to discontinue antibiotics according to a PCT algorithm. Control patients were similar patients admitted before the intervention. Results. The primary endpoint was median antibiotic duration. Overall adverse outcomes at 30 days comprised death, transfer to an intensive care unit, antibiotic side effects, Clostridium difficile infection, disease-specific complications, and post-discharge antibiotic prescription for LRTI. One hundred seventy-four intervention patients and 200 controls were enrolled. Providers complied with the PCT algorithm in 75% of encounters. Procalcitonin-guided therapy reduced median antibiotic duration for pneumonia from 7 days to 6 (P = .045) and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) from 4 days to 3 (P = .01). There was no difference in the rate of adverse outcomes in the PCT and control groups. Conclusions. A PCT-guided algorithm safely reduced the duration of antibiotics for treating LRTI. Utilization of a PCT algorithm may aid antibiotic stewardship efforts. This clinical trial was a single-center, controlled, pre-post study of PCT-guided antibiotic therapy for LRTI. The intervention (incorporation of PCT-guided algorithms) started on April 1, 2017: the preintervention (control group) comprised patients admitted from November 1, 2016 to April 16, 2017, and the postintervention group comprised patients admitted from April 17, 2017 to November 29, 2017 (Supplementary Figure 1). The study comprised patients admitted to the internal medicine services to a medical ward, the Medical Intensive Care Unit (MICU), the Cardiac Intensive Care Unit (CICU), or the Progressive Care Unit (PCU) “step down unit”. The registration data for the trails are in the ClinicalTrials.gov database, number NCT0310910.

KW - Antibiotic stewardship

KW - Clinical trials

KW - Lower respiratory tract infections

KW - Procalcitonin

UR - http://www.scopus.com/inward/record.url?scp=85064201699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064201699&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofy327

DO - 10.1093/ofid/ofy327

M3 - Article

C2 - 30619913

AN - SCOPUS:85064201699

VL - 5

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

SN - 2328-8957

IS - 12

ER -